"CV19 infection may reactivate an

underlying chronic EBV infection

(glandular fever or mono) to result

in more serious illness. This may be

of particular interest to post EBV

ME patients. Co-prescribing of

valaciclovir in the event of CV19

seems like a good idea."

Positive Epstein-Barr virus

detection in corona virus

disease 2019 (COVID-19) patients.

Ting Chen, Jiayi Song, Hongli Liu, 

Hongmei Zheng, Changzheng Chen


This article and extract

remain the property of

its authors

See the full article here.




Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of corona virus disease 2019 (COVID-19) in Wuhan, China. The Objective of this study was to detect the EBV coinfection in COVID-19.



In this retrospective single-center study, we included 67 patients with confirmed COVID-19 in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV seropositive group and seronegative group according to the serological results of EBV, and the characteristics differences between the two groups were compared.



67 COVID-19 patients were included in our study. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, 37 (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV seropositive COVID-19 patients had a 3.09-fold risk of having a fever symptom than EBV seronegative (95%CI, 1.11-8.56; P=0.03). C-reactive protein (CRP) (P=0.02) and the aspartate aminotransferase (AST) (P=0.04) in EBV seropositive COVID-19 patients were higher than that in EBV seronegative patients. EBV seropositive patients had a higher portion of corticosteroid use than the EBV seronegative patients (P=0.03).



EBV acute infection was found in COVID-19 patients. EBV seropositivity was associated with fever and increased inflammation. EBV reactivation may affect the treatment of COVID-19.

Selection of Cohort